Current and new antitumor necrosis factor agents in perspective

[1] *ABB LAB, 2002, HUM PACK INS

[2] *AM COLL RHEUM, FDA ADV COMM REV SAF

[3] BRENNAN FM, 1992, BRIT J RHEUMATOL, V31, P293

[4] *CENT INC, 2002, REM PACK INS

[5] Taming TNF: strategies to restrain this proinflammatory cytokine [J]. IMMUNOLOGY TODAY, 1997, 18 (10): : 487 - 492

[6] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J]. LANCET, 1994, 344 (8930) : 1105 - 1110

[7] ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362

[8] Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 : 163 - 196

[9] Role of cytokines in rheumatoid arthritis [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 : 397 - 440

[10] Geborek P, 2001, AM COLL RHEUM 65 ANN

[1] *ABB LAB, 2002, HUM PACK INS

[2] *AM COLL RHEUM, FDA ADV COMM REV SAF

[3] BRENNAN FM, 1992, BRIT J RHEUMATOL, V31, P293

[4] *CENT INC, 2002, REM PACK INS

[5] Taming TNF: strategies to restrain this proinflammatory cytokine [J]. IMMUNOLOGY TODAY, 1997, 18 (10): : 487 - 492

[6] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J]. LANCET, 1994, 344 (8930) : 1105 - 1110

[7] ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362

[8] Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 : 163 - 196

[9] Role of cytokines in rheumatoid arthritis [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 : 397 - 440

[10] Geborek P, 2001, AM COLL RHEUM 65 ANN